RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancerCourtney Riedinger, Laura Chambers, Paulina Haight et al.|Gynecologic Oncology|2024Cited by 2
Retraction notice to “Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer” [Gynecologic Oncology 183 (2024) 78–84]Courtney Riedinger, Laura Chambers, Floor Backes et al.|Gynecologic Oncology|2024Cited by 1